SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Democrats midterm gains and expected control of Congress are driving selling in DJT, which traders view as a politically sensitive bet on Trumps fortunes. The discussion is overwhelmingly bearish, with many arguing the results weaken the stocks political support, while a few point to the TAE merger as a potential counterweight.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Strong quarterly results and an upbeat outlook tied to AI and data-center demand sparked a rally, but the gains faded as traders worried that a Democratic congressional sweep could bring tighter restrictions on data-center construction. The community is split between bullish investors focused on AMDs growth outlook and traders citing political uncertainty, valuation, and profit-taking as reasons the earnings beat may not sustain the move.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Democratic midterm gains and a Texas political shift have fueled concern that SpaceX could face greater scrutiny of government contracts and obstacles to data-center expansion. Traders are divided between viewing the selloff as political overreaction with the launch and Starlink businesses intact, and expecting prolonged volatility or damage to Musks government-facing plans.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riots announcement of a long-term Corsicana data-center lease with a Frontier AI lab is driving attention, alongside its earnings and the stocks sharp rally. Bulls see the deal as validation of Riots AI-infrastructure pivot, while skeptics question execution, buildout costs and whether the gains will hold.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

Googles credit backstop for financing tied to TeraWulfs Anthropic data-center lease is driving attention; bulls see it as easing funding concerns and potentially pressuring short sellers. Skeptics question whether it resolves the companys debt, construction and permitting risks, and some consider the news overblown.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros strong quarterly results and raised outlook, driven by AI-server demand, are the main focus, but the initial earnings-driven gain faded. Traders are split between bullish views on rapid growth and concerns about thin margins, cash flow, customer concentration, and possible data-center policy risks after the Democratic gains.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers quarterly results and outlook are driving discussion: traders note better-than-expected results and strong bookings and cash generation, but debate whether softer-than-expected forward guidance and weakness in Mobilityamid driver-supply and fuel-cost headwindsjustify the muted stock reaction. Bulls focus on growth and profitability, while bears worry about the core ride business and continued share-price weakness.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisks quarterly sales beat and raised full-year outlook, supported by strong Wegovy pill and broader GLP-1 demand, are driving attention. Bulls see signs of a recovery, while skeptics point to profit pressure, diabetes weakness, Lillys competition and lingering doubts about management and execution.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCrysts third-quarter earnings beat and higher full-year total revenue outlook are drawing attention, alongside FDA approval of ORLADEYO pellets for adolescents and adults. Traders are divided: some see solid commercial momentum, while others question the unchanged ORLADEYO outlook and worry about rising HAE competition, fueling frustration over the stocks muted response to the results.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadogs strong quarterly results were overshadowed by an outlook that roughly matched expectations, prompting a sharp post-earnings selloff as traders focused on potentially slowing growth. The community is split between calling the reaction an overreaction and buying the dip, and warning that high valuation and possible moderation in cloud and AI spending leave further downside risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted...

Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that its management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9...

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for varegacestat, an...

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase...

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the Company) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 1, 2026, the Compensation Committee of the Companys Board of Directors (the Compensation Committee...

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a...

Immunome, Inc. (the Company) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on September 1, 2026, the Compensation Committee of the Companys Board of Directors (the Compensation...

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwrights 28th Annual Global Investment Conference on September 14, 2026, at...

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update. We continue to execute against our strategy of building a...

Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Companys Board of Directors (the Compensation Committee) granted...

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

Why Is IMNM Stock Rising Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Immunome said that the study met its primary endpoint, showing a significant improvement in progression-free survival compared with placebo.</li><li>The trial delivered encouraging efficacy results across key secondary measures, with a confirmed objective response rate at 56% for patients treated with Varegacestat, compared to 9% for those receiving placebo.</li><li>Immunome plans to submit a New Drug Application to the U.S. FDA in the second quarter of 2026.</li></ul>Shares of Immunome Inc. (IMNM)&nbsp;surged more than 12% in on Monday, and reached their highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type of connective tissue tumor.<a href="https://stocktwits.com/symbol/IMNM">IMNM</a> was among the top trending tickers on Stocktwits on Monday morning.<h2 class="st-heading-2">Results Of The Trial</h2>Immunome said that the study met its primary endpoint, showing a significant improvement in progression-free survival compared with placebo. According to the report, the Varegacestat inhibitor reduced the risk of disease progression or death by 84%.The trial also delivered encouraging efficacy results across key secondary measures. The confirmed objective response rate was 56% in patients treated with Varegacestat, compared with 9% in those receiving placebo. Patients also experienced substantial tumor shrinkage, with an exploratory analysis showing a median tumor volume reduction of 83%, compared with tumor growth in the placebo group. Improvements in tumor volume reduction and pain intensity were also statistically significant.Varegacestat was generally well tolerated, with most side effects reported as mild to moderate. The most common adverse events included diarrhea, fatigue, rash, cold, and nausea. Based on these results, Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration (USFDA) in the second quarter of 2026.“Desmoid tumors can have a devastating physical and emotional impact on patients given their unpredictable nature and the limitations of current treatment options. The progression-free survival benefit, high response rate and reduction in tumor volume with varegacestat in the RINGSIDE trial are striking. These findings elevate the role of GSIs and confirm varegacestat could become standard of care in the treatment of desmoid tumors,” said Mrinal M. Gounder, sarcoma medical oncologist and drug development specialist at Memorial Sloan Kettering Cancer Center, and RINGSIDE primary investigator.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:910/85;" src="https://news.stocktwits-cdn.com/IMNM_png_16a0580d53.webp" alt="IMNM.png" width="910" height="85"><figcaption>IMNM's Sentiment Meter and Message Volumes at 09:30 a.m. ET on Dec. 15, 2025 | Source: Stocktwits</figcaption></figure>One user expects the stock to potentially double in value.<stembedurl>https://stocktwits.com/Camtanren/message/639163616</stembedurl>Year-to-date, the stock has gained more than 80%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/is-the-nasdaq-composite-getting-ready-for-a-short-term-correction/cLe42UrREo4">Is The Nasdaq Composite Getting Ready For A Short-Term Correction? Chart Shows A Lower High And Approach Toward 50-DMA</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type of connective tissue tumor.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$20.31
Prev Close	$19.59
Open	$19.81
Dividend Yield	0.00%
50-Day Moving Average	$22.11
Beta	1.67
Avg. Volume	1.38M
PE Ratio	-8.04

52-Week High	$30.06
52-Week Low	$14.64
Market Capitalization	$2.4B
EPS (Annual)	-$2.43
Price to Book	4.39
Revenue Per Employee	$39,214.69

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMNM Fundamentals